胸壁 bolus 对接受 IMRT 的乳腺癌根治术后患者临床结局的影响:来自中国的数据
该回顾性研究纳入 2014 至 2019 年在青岛大学附属医院接受光子 IMRT 的乳腺癌根治术后浸润性癌患者 529 例,其中 254 例(48%)每日使用 bolus。经倾向性评分匹配后 175 例配对良好,中位随访 60 个月。结果显示每日使用 5 mm 胸壁 bolus 与未改善的临床结局相关,且 bolus 与皮肤毒性(P = 0.555)及晚期肺炎(P = 0.333)无相关性。
要点
- IMRT 技术下局部复发率低,但每日使用 5 mm 胸壁 bolus 未与更好的临床结局相关。
- 匹配后 bolus 组与无 bolus 组的 5 年局部复发累积发生率分别为 2.42% 与 2.38%。
- bolus 使用与皮肤毒性(P = 0.555)及晚期肺炎(P = 0.333)无相关性。
核心结论
- 研究显示使用 IMRT 技术时复发率低,每日使用 5 mm 胸壁 bolus 与未改善的临床结局相关。
研究设计与样本
- 回顾性研究纳入 2014 至 2019 年在青岛大学附属医院接受乳房切除术后光子 IMRT 的浸润性癌患者((y)pT0-4、(y)pN0-3)。
- 共纳入 529 例患者,其中 254 例(48%)接受 bolus 应用,根据是否每日使用 bolus 分为两组,并使用倾向性评分匹配(PSM)匹配基线特征。
- 中位随访时间为 60 个月,匹配后选取 175 例配对良好的患者。
主要发现
- 匹配后,接受 bolus 与未接受 bolus 患者的校正 5 年结局(95% 置信区间)分别为:局部复发累积发生率 2.42%(0.04-4.74)对 2.38%(0.05-4.65)。
- 局部区域复发累积发生率分别为 2.42%(0.04-4.74)对 3.59%(0.73-6.37)。
- 无病生存率分别为 88.12%(83.35-93.18)对 84.69%(79.42-90.30)。
- 总生存率分别为 94.21%(90.79-97.76)对 95.86%(92.91-98.91)。
- 未观察到 bolus 应用与皮肤毒性(P = 0.555)及晚期肺炎(P = 0.333)之间存在相关性。
关键数值与推荐
- 匹配后 bolus 组与无 bolus 组的 5 年局部复发累积发生率分别为 2.42%(95%CI 0.04-4.74)与 2.38%(95%CI 0.05-4.65)。
- 匹配后 bolus 组与无 bolus 组的 5 年局部区域复发累积发生率分别为 2.42%(95%CI 0.04-4.74)与 3.59%(95%CI 0.73-6.37)。
- 匹配后 bolus 组与无 bolus 组的 5 年无病生存率分别为 88.12%(95%CI 83.35-93.18)与 84.69%(95%CI 79.42-90.30)。
- 匹配后 bolus 组与无 bolus 组的 5 年总生存率分别为 94.21%(95%CI 90.79-97.76)与 95.86%(95%CI 92.91-98.91)。
- bolus 应用与皮肤毒性(P = 0.555)及晚期肺炎(P = 0.333)无相关性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aims to investigate the effects of chest wall bolus in intensity-modulated radiotherapy (IMRT) technology on clinical outcomes for post-mastectomy breast cancer patients. MATERIALS AND METHODS: This retrospective study included patients with invasive carcinoma ((y)pT0-4, (y)pN0-3) who received photon IMRT after mastectomy at the Affiliated Hospital of Qingdao University from 2014 to 2019. The patients were divided into two groups based on whether they received daily bolus application or not, and the baseline characteristics were matched using propensity score matching (PSM). Cumulative incidence (CI) of local recurrence (LR), locoregional recurrence (LRR), overall survival (OS) and disease-free survival (DFS) were evaluated with a log-rank test. Acute skin toxicity and late radiation pneumonia was analyzed using chi-square test. RESULTS: A total of 529 patients were included in this study, among whom 254 (48%) patients received bolus application. The median follow-up time was 60 months. After matching, 175 well-paired patients were selected. The adjusted 5-year outcomes (95% confidence interval) in patients treated with and without bolus were, respectively: CI of LR 2.42% (0.04-4.74) versus 2.38% (0.05-4.65), CI of LRR 2.42% (0.04-4.74) versus 3.59% (0.73-6.37), DFS 88.12% (83.35-93.18) versus 84.69% (79.42-90.30), OS 94.21% (90.79-97.76) versus 95.86% (92.91-98.91). No correlation between bolus application and skin toxicity (P = 0.555) and late pneumonia (P = 0.333) was observed. CONCLUSIONS: The study revealed a low recurrence rate using IMRT technology. The daily used 5 mm chest wall bolus was not associated with improved clinical outcomes.
引用
- Jiang T, Tian J, Lei P, et al. The impact of bolus on clinical outcomes for post-mastectomy breast cancer patients treated with IMRT: data from China. Radiat Oncol. 2024. PMID: 38807176. doi:10.1186/s13014-024-02456-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。